Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
Advances in Vulvar Cancer Biology and Management.
Chehade R, Jerzak KJ, Tavanger F, Plotkin A, Gien LT, Leung E, Mackay H. Chehade R, et al. Among authors: mackay h. J Clin Oncol. 2025 Jan;43(1):89-100. doi: 10.1200/JCO.24.01071. Epub 2024 Oct 31. J Clin Oncol. 2025. PMID: 39481051 Review.
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Lee JM, et al. Among authors: mackay h. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. doi: 10.1200/JCO.24.00683. Epub 2024 Oct 3. J Clin Oncol. 2024. PMID: 39361946 Clinical Trial.
USP50 suppresses alternative RecQ helicase use and deleterious DNA2 activity during replication.
Mackay HL, Stone HR, Ronson GE, Ellis K, Lanz A, Aghabi Y, Walker AK, Starowicz K, Garvin AJ, Van Eijk P, Koestler SA, Anthony EJ, Piberger AL, Chauhan AS, Conway-Thomas P, Vaitsiankova A, Vijayendran S, Beesley JF, Petermann E, Brown EJ, Densham RM, Reed SH, Dobbs F, Saponaro M, Morris JR. Mackay HL, et al. Nat Commun. 2024 Sep 16;15(1):8102. doi: 10.1038/s41467-024-52250-4. Nat Commun. 2024. PMID: 39284827 Free PMC article.
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. Creutzberg CL, et al. Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. Lancet Oncol. 2024. PMID: 39214113
Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
Volinsky-Fremond S, Horeweg N, Andani S, Barkey Wolf J, Lafarge MW, de Kroon CD, Ørtoft G, Høgdall E, Dijkstra J, Jobsen JJ, Lutgens LCHW, Powell ME, Mileshkin LR, Mackay H, Leary A, Katsaros D, Nijman HW, de Boer SM, Nout RA, de Bruyn M, Church D, Smit VTHBM, Creutzberg CL, Koelzer VH, Bosse T. Volinsky-Fremond S, et al. Among authors: mackay h. Nat Med. 2024 Jul;30(7):2092. doi: 10.1038/s41591-024-03126-z. Nat Med. 2024. PMID: 38951637 Free PMC article. No abstract available.
PARP inhibitors in non-ovarian gynecologic cancers.
Fernandes I, Chehade R, MacKay H. Fernandes I, et al. Among authors: mackay h. Ther Adv Med Oncol. 2024 Jun 12;16:17588359241255174. doi: 10.1177/17588359241255174. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38882441 Free PMC article. Review.
Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
Volinsky-Fremond S, Horeweg N, Andani S, Barkey Wolf J, Lafarge MW, de Kroon CD, Ørtoft G, Høgdall E, Dijkstra J, Jobsen JJ, Lutgens LCHW, Powell ME, Mileshkin LR, Mackay H, Leary A, Katsaros D, Nijman HW, de Boer SM, Nout RA, de Bruyn M, Church D, Smit VTHBM, Creutzberg CL, Koelzer VH, Bosse T. Volinsky-Fremond S, et al. Among authors: mackay h. Nat Med. 2024 Jul;30(7):1962-1973. doi: 10.1038/s41591-024-02993-w. Epub 2024 May 24. Nat Med. 2024. PMID: 38789645 Free PMC article.
364 results